Trial Profile
Phase III Trial of Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease: a 26 Weeks, Randomized, Double-blind, Double-dummy, Placebo- and Positive- Parallel Controlled and Extended Single Arm to 54 Weeks Multicentre Study
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Octohydroaminoacridine succinate (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 12 Oct 2017 Last checked against ClinicalTrials.gov record
- 18 Sep 2017 New trial record